Samer Al Hadidi: Quadruplets as Top Option in Transplant-Ineligible Multiple Myeloma
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on LinkedIn:
“Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy.”
In the video, Samer Al Hadidi discusses the IMROZ and CEPHEUS studies:
The IMROZ and CEPHEUS studies focused on patients who were ineligible for or not intended to undergo transplants, often due to advanced age or decisions made by patients and their physicians.
In the IMROZ study, progression-free survival (PFS) was improved with the Isa-RVd regimen compared to RVd. Similarly, the CEPHEUS study demonstrated deeper responses and improved PFS for patients receiving Dara-RVd compared to RVd, with higher rates of complete response (CR) or better and measurable residual disease (MRD) negativity, despite the shorter follow-up duration.
Both studies highlighted potential adverse event (AE) concerns, especially in older or frailer patients. In the IMROZ study, grade 3 or higher neutropenia, hematological toxicities, and infections were noted. These findings underscore the need for careful monitoring of AEs when using triplet or quadruplet regimens in this vulnerable population.
More posts featuring Samer Al Hadidi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023